Autolus Therapeutics Receives Prix Galien UK Award

LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product.

14.05.2026

Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UK Company achieves positive gross margin for the acute lymphoblastic leukemia (ALL) business Cost reduction initiative to drive gross profit margin improvement and path to profitability for the ALL business underway Obe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS) Conference call to be held today at 8:30am EDT/1:30pm BST: conference call participants should pre-register using the link at the bottom of this press release LONDON and GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announces its operational and financial results for the first quarter ended March 31, 2026.

29.04.2026

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Initiative focused on driving gross profit margin and path to profitability for the ALL business Company will reduce headcount by approximately 13% while doubling manufacturing of products for commercial and clinical trial patients in 2026 Autolus reiterates full year 2026 AUCATZYL® net product revenue of $120 million to $135 million, up from $74 million in 2025, as well as an anticipated shift to positive gross margin in 2026 Clinical development programs are on track and include CATULUS, a pivotal Phase 2 trial in pediatric relapsed/refractory acute lymphoblastic leukemia; LUMINA, a pivotal Phase 2 trial in lupus nephritis; and BOBCAT, an exploratory Phase 1 trial in progressive multiple sclerosis LONDON and GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced a strategic initiative and plan to improve operational efficiency and reduce operating expenses.

21.04.2026

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 68,500 American Depositary Shares and 57,765 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 15 employees pursuant to the Company's 2025 Inducement Plan.

Autolus Therapeutics plc (AUTL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Autolus Therapeutics plc (AUTL)

Autolus Therapeutics Receives Prix Galien UK Award

Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript

Autolus Therapeutics Q1 Earnings Call Highlights

Videolar

No Data

Press-relizlar

Autolus Therapeutics Receives Prix Galien UK Award

Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics Receives Prix Galien UK Award

Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript

Autolus Therapeutics Q1 Earnings Call Highlights

Videolar

No Data

Press-relizlar

Autolus Therapeutics Receives Prix Galien UK Award

Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Autolus Therapeutics plc (AUTL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Autolus Therapeutics plc (AUTL)

Autolus Therapeutics Receives Prix Galien UK Award

Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript

Autolus Therapeutics Q1 Earnings Call Highlights

Videolar

No Data

Press-relizlar

Autolus Therapeutics Receives Prix Galien UK Award

Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics Receives Prix Galien UK Award

Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript

Autolus Therapeutics Q1 Earnings Call Highlights

Videolar

No Data

Press-relizlar

Autolus Therapeutics Receives Prix Galien UK Award

Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)